Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07209267 · ClinicalTrials.gov registry record · Phase 2
Baricitinib Curative Repression of HIV-1
A Phase 2 study, sponsored by Emory University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT07209267 is a Phase 2 study that has not yet begun recruiting, run by Emory University. The registered enrollment target is 20 participants.
The verdict
NCT07209267, a Phase 2 study, has not yet begun recruiting, sponsored by Emory University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is being done to test whether a drug called baricitinib, which blocks specific causes of inflammation, affects HIV-1 viral rebound and viral load levels after HIV treatment is discontinued. Researchers will test the effects of continuing baricitinib in people with HIV before and after discontinuing their antiretroviral therapy. This drug is approved by the Food and Drug Administration (FDA) for other diseases; it is not approved for the treatment of HIV-1. The study team will also investigate any side effects associated with the drug.
Interventions
- DRUG Baricitinib (LY3009104) 2 mg
- DRUG Antiretroviral Therapy (ART)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07209267
The ClinicalTrials.gov registry entry for NCT07209267 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Baricitinib (LY3009104) 2 mg is the first listed.
NCT07209267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07209267 about?
NCT07209267 is a clinical study titled "Baricitinib Curative Repression of HIV-1". This study is being done to test whether a drug called baricitinib, which blocks specific causes of inflammation, affects HIV-1 viral rebound and viral load levels after HIV treatment is discontinued. Researchers will test the effects of continuing baricitinib in people with HIV before and after dis...
What is the current status of trial NCT07209267?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-07. Estimated completion is 2028-01.
What interventions are being tested in trial NCT07209267?
The interventions under investigation include: Baricitinib (LY3009104) 2 mg (DRUG), Antiretroviral Therapy (ART) (DRUG).
Who is sponsoring clinical trial NCT07209267?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.